SG11201809542XA - Methods of immunotherapy - Google Patents

Methods of immunotherapy

Info

Publication number
SG11201809542XA
SG11201809542XA SG11201809542XA SG11201809542XA SG11201809542XA SG 11201809542X A SG11201809542X A SG 11201809542XA SG 11201809542X A SG11201809542X A SG 11201809542XA SG 11201809542X A SG11201809542X A SG 11201809542XA SG 11201809542X A SG11201809542X A SG 11201809542XA
Authority
SG
Singapore
Prior art keywords
international
qld
pct
rule
methods
Prior art date
Application number
SG11201809542XA
Inventor
Rajiv Khanna
Corey Smith
Original Assignee
Council Queensland Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Queensland Inst Medical Res filed Critical Council Queensland Inst Medical Res
Publication of SG11201809542XA publication Critical patent/SG11201809542XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96436—Granzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 0 1111111011111111101 11111111010111110010101111111111011111111111111111011110111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2017/203356 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: G01N 33/50 (2006.01) C12N 5/0783 (2010.01) A61K 35/17 (2015.01) (21) International Application Number: PCT/IB2017/000705 (22) International Filing Date: 25 May 2017 (25.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/341,360 25 May 2016 (25.05.2016) US 62/487,814 20 April 2017 (20.04.2017) US (71) Applicant: THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH [AU/AU]; 300 Herston Rd., Herston, QLD 4006 (AU). (72) Inventors: KHANNA, Rajiv; 59 Aberleigh Road, Harston, QLD 4006 (AU). SMITH, Corey; 56 St. Vincent Street, Ashgrove, QLD 4060 (AU). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (84) under Rule 4.17: Declarations of inventorship (Rule 4.17(iv)) — ,— I Published: ..! — — in M with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) M 0 N _ N (54) Title: METHODS OF IMMUNOTHERAPY 1-1 0 (57) : Provided herein are methods and compositions related to the selection T cells and/or subjects for adoptive immunother- ei apy based on the expression of one or more biomarkers selected from granzyme B, granzyme K, perforin, CD8, PD-1, TIM-3, LAG-3, 0 CTLA-4, CD107a, IFNg, IL-2, TNF and CD4.
SG11201809542XA 2016-05-25 2017-05-25 Methods of immunotherapy SG11201809542XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341360P 2016-05-25 2016-05-25
US201762487814P 2017-04-20 2017-04-20
PCT/IB2017/000705 WO2017203356A1 (en) 2016-05-25 2017-05-25 Methods of immunotherapy

Publications (1)

Publication Number Publication Date
SG11201809542XA true SG11201809542XA (en) 2018-12-28

Family

ID=60411116

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007893TA SG10202007893TA (en) 2016-05-25 2017-05-25 Methods of immunotherapy
SG11201809542XA SG11201809542XA (en) 2016-05-25 2017-05-25 Methods of immunotherapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202007893TA SG10202007893TA (en) 2016-05-25 2017-05-25 Methods of immunotherapy

Country Status (13)

Country Link
US (1) US11478508B2 (en)
EP (1) EP3465203A4 (en)
JP (2) JP7270382B2 (en)
KR (2) KR20190028662A (en)
CN (1) CN109477830A (en)
AU (1) AU2017271122B2 (en)
BR (1) BR112018072305A2 (en)
CA (1) CA3023820A1 (en)
MX (1) MX2018013963A (en)
NZ (1) NZ749136A (en)
RU (1) RU2756276C2 (en)
SG (2) SG10202007893TA (en)
WO (1) WO2017203356A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ749136A (en) 2016-05-25 2023-11-24 Council Queensland Inst Medical Res Methods of immunotherapy
JP2020506901A (en) * 2017-01-20 2020-03-05 アタラ バイオセラピューティクス，インコーポレーテッド Method for treating multiple sclerosis using autologous T cells
US20220033774A1 (en) * 2018-04-16 2022-02-03 The Regents Of The University Of California Compositions and methods for cytotoxic cd4+ t cells
US20210238550A1 (en) * 2018-07-31 2021-08-05 Thyas Co. Ltd. METHOD FOR PRODUCING REGENERATED T CELL POPULATION VIA iPS CELLS

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009448A1 (en) 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
IL155610A0 (en) 2000-11-01 2003-11-23 Univ California Immunomodulatory peptides derived from heat shock proteins and uses thereof
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
PL214283B1 (en) 2002-08-08 2013-07-31 Baylor College Medicine Isolation and identification of t cells
EP1880220A2 (en) 2005-05-13 2008-01-23 University Of Miami Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease
US20080131415A1 (en) * 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US8629098B2 (en) * 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
US20090324630A1 (en) 2008-04-21 2009-12-31 Jensen Michael C Fusion multiviral chimeric antigen
US20150064206A1 (en) 2008-04-28 2015-03-05 Txcell Compositions for treating uveitis
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
MX359513B (en) * 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res METHOD and COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY.
WO2012131419A1 (en) 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
EP4285922A1 (en) 2011-05-26 2023-12-06 Geneius Biotechnology Investments, LLC Modulated immunodominance therapy
AU2012351347B2 (en) 2011-12-12 2016-05-19 Baylor College Of Medicine Process of expanding T cells
DK2900061T3 (en) 2012-09-17 2020-03-02 Galectin Therapeutics Inc PROCEDURE FOR ENHANCING SPECIFIC IMMUNTERPRISES IN CANCER TREATMENT
EP2903637B1 (en) * 2012-10-02 2019-06-12 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014083201A1 (en) * 2012-11-30 2014-06-05 Red Flag Diagnostics Gmbh Method for determining compatibility between a donor and a recipient by means of the flow cytometric detection of alloreactive t cells
MX2015013104A (en) * 2013-03-15 2016-06-16 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy.
ES2899703T3 (en) 2013-06-21 2022-03-14 Inst Nat Sante Rech Med Markers of long-term renal graft dysfunction
EP2982746A1 (en) 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
RU2558294C1 (en) 2014-09-16 2015-07-27 Общество с ограниченной ответственностью "НекстГен" Codon-optimised recombinant plasmid, stimulation technique for peripheral nerve regeneration, treatment modality for damaged human nerve
SG11201703406YA (en) * 2014-11-05 2017-05-30 Sloan Kettering Inst Cancer Methods of selecting t cell line and donor thereof for adoptive cellular therapy
CA2984178C (en) 2015-05-12 2023-10-31 Memorial Sloan Kettering Cancer Center Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
EP3851110A1 (en) 2015-05-28 2021-07-21 Kite Pharma, Inc. Methods of conditioning patients for t cell therapy
NZ749136A (en) 2016-05-25 2023-11-24 Council Queensland Inst Medical Res Methods of immunotherapy
MX2018013959A (en) 2016-05-25 2019-08-22 Council Queensland Inst Medical Res Methods of treating autoimmune disease using allogeneic t cells.
JP2020506901A (en) 2017-01-20 2020-03-05 アタラ バイオセラピューティクス，インコーポレーテッド Method for treating multiple sclerosis using autologous T cells

Also Published As

Publication number Publication date
US11478508B2 (en) 2022-10-25
RU2018145503A3 (en) 2020-10-02
AU2017271122B2 (en) 2023-10-26
AU2017271122A1 (en) 2019-01-03
EP3465203A4 (en) 2020-07-29
JP7270382B2 (en) 2023-05-10
SG10202007893TA (en) 2020-10-29
KR102592673B1 (en) 2023-10-24
CA3023820A1 (en) 2017-11-30
EP3465203A1 (en) 2019-04-10
NZ749136A (en) 2023-11-24
MX2018013963A (en) 2019-08-22
JP2019522786A (en) 2019-08-15
RU2756276C2 (en) 2021-09-29
KR20190028662A (en) 2019-03-19
WO2017203356A1 (en) 2017-11-30
US20210228628A1 (en) 2021-07-29
KR20220162853A (en) 2022-12-08
JP2022078036A (en) 2022-05-24
BR112018072305A2 (en) 2019-02-12
CN109477830A (en) 2019-03-15
RU2018145503A (en) 2020-06-25

Similar Documents

Publication Publication Date Title
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201808990QA (en) Compositions for topical application of compounds
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201901642XA (en) Constitutively active cytokine receptors for cell therapy
SG11201908088RA (en) Antibodies against pd-l1
SG11201808678QA (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions
SG11201907857RA (en) Edible and biodegradable utensils
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201408787PA (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201807426WA (en) Immunomodulators
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201407190TA (en) Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201908796XA (en) Improved antigen binding receptors
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201903032SA (en) Methods and compositions related to nk cell and anti-pdl1 cancer therapies
SG11201809542XA (en) Methods of immunotherapy
SG11201407200TA (en) Liquid formulation
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201908472VA (en) Compositions and methods for activating nk cells
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201909041SA (en) Anti-pd-l1 antibody and use thereof